Akebia Therapeutics
AKBA
90 hedge funds and large institutions have $16.5M invested in Akebia Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 32 reducing their positions, and 16 closing their positions.
521% more call options, than puts
Call options by funds: $292K | Put options by funds: $47K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.94% less ownership
Funds ownership: 31.33% → 28.39% (-2.9%)
6% less funds holding
Funds holding: 96 → 90 (-6)
18% less capital invested
Capital invested by funds: $20.2M → $16.5M (-$3.69M)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
47% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$602K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$496K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$191K |
| 4 |
Two Sigma Investments
New York
|
+$127K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.21M |
| 2 |
Millennium Management
New York
|
-$735K |
| 3 |
HF
HRT Financial
New York
|
-$424K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$304K |
| 5 |
E
Ergoteles
New York
|
-$268K |
AKBA Hedge Fund Activity: Q3 2022 in Review
90 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2022, worth a combined $16.5M — down 18% from $20.2M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AKBA and 12 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 17 added.
The largest buyer was Renaissance Technologies, adding an estimated $602K. The largest seller was Vanguard Group, cutting an estimated $1.21M.
- 90 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2022, down from 96 in Q2 2022.
- Funds reported $16.5M of Akebia Therapeutics stock for Q3 2022, down 18% quarter-over-quarter.
- 12 funds opened new Akebia Therapeutics positions in Q3 2022 and 16 closed out, a net change of -4 holders.
- The largest Akebia Therapeutics buyer in Q3 2022 was Renaissance Technologies, an estimated $602K added.
- The largest Akebia Therapeutics seller in Q3 2022 was Vanguard Group, an estimated $1.21M sold.
Based on aggregated 13F filings for Q3 2022.